Therapeutic Goods Administration, August 30, 2017
Consumers and health professionals are advised that Australasian Medical and Science Ltd (AMSL), in consultation with the TGA, has issued a hazard alert for Essure. AMSL is also recallingunused stock and withdrawing the device from the Australian market.
Read more of Essure contraceptive device: Hazard Alert
Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...
Pharmacy News, 19 May, 2017
The TGA has agreed that consumer advertising should be allowed for the emergency contraceptive ulipristal.
This will help increase public awareness and access to ulipristal (branded EllaOne) and therefore reduce unplanned pregnancies, says the TGA.
Read more here
Gay News Network, Wednesday 18 January 2017 The Victorian AIDS Council has announced it will give an additional $100,000 to the PrEPX trial to fund access to pre-exposure prophylaxis for HIV (PrEP) for 600 Victorians at risk. VAC’s announcement comes months after PrEPX reached capacity for men living in metropolitan Melbourne. The VAC said there is already a substantial waiting list for those...
Jay Weatherill MP, Nat Cook MP, Wednesday, November 29, 2016 South Australians at high risk of contracting HIV will have access to the latest preventative technology study, as part of a State Government commitment announced today. Pre-exposure prophylaxis or PrEP is the latest prevention therapy in the fight against HIV. Under a PrEP access trial, eligible South Australians who don’t have HIV and...
SHine SA, October 2016 SHine SA and Family Planning Alliance Australia put in submissions to the TGA for the rescheduling of ulipristal acetate (EllaOne®), a new emergency contraceptive pill in Australia. The rescheduling is from prescription-only to Schedule 3 (available in pharmacies with a pharmacy consultation). This has now been approved, to take place from February 2017. This is an...